Hot Features
Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health ... Definium Therapeutics, Inc., a clinical biopharmaceutical company, develops novel product candidates to treat brain health disorders. The company’s lead product candidates DT120, which is in phase 3 for the treatment of generalized anxiety disorder, major depressive disorder, and other brain health disorders; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc. and changed its name to Definium Therapeutics, Inc. in January 2026. Definium Therapeutics, Inc. is headquartered in New York, New York. Show more
| Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 0.2 | 0.879120879121 | 22.75 | 25.16 | 21.69 | 2930743 | 23.52565999 | CS |
| 4 | 1.76 | 8.30580462482 | 21.19 | 25.16 | 19.33 | 2062365 | 22.87618424 | CS |
| 12 | 4.91 | 27.2172949002 | 18.04 | 26.25 | 17.13 | 1886129 | 21.79670268 | CS |
| 26 | 7.46 | 48.1601032924 | 15.49 | 26.25 | 14.74 | 1801749 | 20.06236883 | CS |
| 52 | 7.46 | 48.1601032924 | 15.49 | 26.25 | 14.74 | 1801749 | 20.06236883 | CS |
| 156 | 7.46 | 48.1601032924 | 15.49 | 26.25 | 14.74 | 1801749 | 20.06236883 | CS |
| 260 | 7.46 | 48.1601032924 | 15.49 | 26.25 | 14.74 | 1801749 | 20.06236883 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales
Vous avez déjà un compte? Connexion
Vous n'avez pas de compte ? Inscription
En m'inscrivant, je confirme avoir lu, compris et accepté les Conditions générales d'ADVFN et j'affirme etre un investisseur privé.